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Summary
Background Several studies have reported associations between radiation toxicity and single nucleotide poly morphisms 
(SNPs) in candidate genes. Few associations have been tested in independent validation studies. This prospective 
study aimed to validate reported associations between genotype and radiation toxicity in a large independent dataset.
Methods 92 (of 98 attempted) SNPs in 46 genes were successfully genotyped in 1613 patients: 976 received adjuvant 
breast radiotherapy in the Cambridge breast IMRT trial (ISRCTN21474421, n=942) or in a prospective study of breast 
toxicity at the Christie Hospital, Manchester, UK (n=34). A further 637 received radical prostate radiotherapy in the 
MRC RT01 multicentre trial (ISRCTN47772397, n=224) or in the Conventional or Hypofractionated High Dose 
Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP) trial (ISRCTN97182923, n=413). Late toxicity was 
assessed 2 years after radiotherapy with a validated photographic technique (patients with breast cancer only), clinical 
assessment, and patient questionnaires. Association tests of genotype with overall radiation toxicity score and 
individual endpoints were undertaken in univariate and multivariable analyses. At a type I error rate adjusted for 
multiple testing, this study had 99% power to detect a SNP, with minor allele frequency of 0·35, associated with a per 
allele odds ratio of 2·2.
Findings None of the previously reported associations were conﬁ rmed by this study, after adjustment for multiple 
comparisons. The p value distribution of the SNPs tested against overall toxicity score was not diﬀ erent from that 
expected by chance.
Interpretation We did not replicate previously reported late toxicity associations, suggesting that we can essentially 
exclude the hypothesis that published SNPs individually exert a clinically relevant eﬀ ect. Continued recruitment of 
patients into studies within the Radio genomics Consortium is essential so that suﬃ  ciently powered studies can be 
done and methodological challenges addressed.
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Campaign, Cambridge National Institute of Health Research (NIHR) Biomedical Research Centre, Experimental 
Cancer Medicine Centre, East Midlands Innovation, the National Cancer Institute, Joseph Mitchell Trust, Royal 
Marsden NHS Foundation Trust, Institute of Cancer Research NIHR Biomedical Research Centre for Cancer.
Introduction
Late side-eﬀ ects from radiotherapy are often irreversible, 
can decrease health-related quality of life, and limit 
treatment intensity in radical radiotherapy regimens. 
Quantiﬁ cation of late toxicity is therefore crucial in 
assessment of the therapeutic beneﬁ t of radiotherapy, 
and recommendations for its reporting have been made.1,2 
If the hypothesis that there is a sizeable subpopulation of 
patients who have a signiﬁ cantly increased risk of 
developing toxicity proves correct, it is likely that this 
subset of cases currently limits our ability to maximise 
toxicity-free local control through higher doses of 
radiation to the remaining cases. The RAPPER 
(Radiogenomics: Assessment of Polymorphisms for 
Predicting the Eﬀ ects of Radiotherapy) study was 
designed to identify common genetic variation associated 
with the development of late radiation toxicity3 as a ﬁ rst 
step in the process of identifying such a subset of toxicity-
prone patients.
Apart from one small genome-wide study,4 single 
nucleotide polymorphism (SNP) association studies of 
radiotherapy toxicity published to date have used a 
candidate gene approach. Radiation-induced cell killing, 
for which DNA damage is a major mechanism, is thought 
to be a triggering event in the development of radiotherapy 
toxicity. Additionally, the release of cytokines5 is thought 
to initiate biological responses in multiple cell types 
leading to the development of late toxicity. The focus of 
candidate gene studies has thus been on genes involved 
in DNA damage recognition and repair (eg, ATM, BRCA1, 
BRCA2, and TP53), free radical scavenging (eg, SOD2), 
and anti-inﬂ ammatory response (eg, TGFB1). Studies to 
date, reviewed recently,6–8 have been underpowered, 
including fewer than 500 samples; they have tested many 
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SNPs without adjusting for multiple comparisons and 
ﬁ ndings have proved diﬃ  cult to replicate. No individual 
SNP or combined risk SNP signature9–14 has yet been 
validated as a risk factor for radiation toxicity.
We aimed to conﬁ rm reported associations between 
candidate SNPs or SNP signatures and radiation toxicity 
in a large, well powered prospective study of patients 
with breast and prostate cancer.
Methods
Patients
1613 patients from four studies were included in 
this analysis. Treatment was given according to the 
component study protocols and details were recorded for 
all patients.
Samples were obtained from 942 of 1145 women 
recruited into the Cambridge breast IMRT trial 
(ISRCTN21474421) who underwent conservative surgery 
followed by adjuvant radiotherapy.15 In this study, patients 
with signiﬁ cant dose inhomogeneities, deﬁ ned by a 
volume of 2 cm³ or more exceeding 107% of the prescribed 
dose, were randomly assigned to receive either standard 
breast radiotherapy (control) or a straightforward method 
of forward-planned intensity modulated radiotherapy 
(IMRT; intervention). 34 samples were from patients 
enrolled in a prospective study of breast toxicity in women 
who received conservative surgery and adjuvant 
radiotherapy at the Christie Hospital (Manchester, UK). 
Blood samples were also obtained for 224 of the 
843 patients with localised prostate cancer randomly 
assigned in the MRC RT01 multi-centre trial 
(ISRCTN47772397) to standard-dose or escalated-dose 
conformal radiotherapy after neoadjuvant androgen 
suppression.16–18 At the time of initial analysis in June, 
2009, for the study we report here, 647 patients had been 
recruited to both the Conventional or Hypo fractionated 
High Dose Intensity Modulated Radiotherapy for Prostate 
Cancer (CHHiP) trial (ISRCTN97182923) and the 
RAPPER study, and 2-year toxicity data were available for 
analysis for 413 patients. CHHiP patients with localised 
prostate cancer underwent IMRT after neoadjuvant 
androgen suppression and were randomly assigned to 
one of three dose schedules.19 Recruitment to both the 
CHHiP and RAPPER studies was ongoing at the date of 
data release.
The RAPPER study (UKCRN1471) reported here is a 
large UK sample collection study, opened in 2005, which 
recruits patients from clinical trials and other well 
designed studies. All patients in the Cambridge IMRT and 
Manchester prospective trials were oﬀ ered recruitment to 
RAPPER when they enrolled in the component study; 
blood samples were taken for RAPPER before radiotherapy. 
Patients recruited to the MRC RT01 trial and under 
continuing follow-up in 2005 were oﬀ ered participation in 
the RAPPER study at a follow-up appointment; blood 
samples were therefore taken at least 2 years after the start 
of their radiotherapy. The distribution of toxicity in patients 
recruited to RT01 but not RAPPER was broadly similar to 
that seen in patients recruited to both RT01 and RAPPER 
(data not shown). CHHiP patients could be recruited to 
the RAPPER study either concurrently or after consenting 
to participate in the CHHiP trial. Toxicity data for all 
patients were obtained prospectively within the component 
clinical trial. RAPPER is approved by the Cambridgeshire 
Figure 1: Trial proﬁ le
IMRT=intensity modulated radiotherapy. *One patient was not randomised because the standard plan was unacceptable, owing to a signiﬁ cant region of low dose, so IMRT was prescribed; patient was 
withdrawn from the late toxicity analysis. 
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421 standard dose 
         (64 Gy/32 f)
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114 toxicity data 
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Dose inhomogeneity
1145 patients recruited to Cambridge IMRT trial 
and underwent 3D imaging and dosimetry
calculated with standard breast pain
Ongoing recruitment to Manchester 
prospective toxicity study
Randomised
Ongoing recruitment to CHHiP and 
RAPPER studies, data release 
June 17, 2009
Dosimetry adequate
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2 Research Ethics Committee (05/Q0108/365). All patients 
gave written informed consent for use of their samples in 
genetic research. Figure 1 shows the trial proﬁ le for the 
RAPPER study.
Procedures
Data were obtained for age, smoking history, diabetes 
mellitus, and acute radiotherapy toxicity. In patients with 
breast cancer, body-mass index, use of tamoxifen and 
chemotherapy, breast boost, breast volume, ethnic origin, 
cardiovascular disease, and cosmesis after surgery were 
also recorded. In patients with prostate cancer, data for 
hypertension, previous surgery, clinical stage, risk of 
seminal vesicle involvement, prescribed dose, and 
baseline symptoms were also documented.
Toxicity was recorded with standardised scoring 
systems; the scales and incidence of each toxicity endpoint 
used (acute and late toxicity) are shown in appendix 1. An 
eﬀ ect of poor surgical cosmesis on clinical assessment of 
breast shrinkage or induration at 2 years has been 
reported for patients in the IMRT trial;15 thus, endpoints 
that accurately reﬂ ect late toxicity, due to radiotherapy 
rather than surgery, were used (appendix 1). Details of the 
methods used are available elsewhere.15
For patients with prostate cancer, ﬁ ve rectal (bleeding, 
proctitis, sphincter control, stool frequency, tenesmus) 
and four urinary endpoints (frequency, nocturia, 
incontinence, and decreased stream) were chosen to 
represent the range of rectal and bladder toxicity reported 
by patients 2 years after radiotherapy to the prostate. The 
rectal endpoints have previously shown a dose-volume 
response for at least one dose level with the volume of 
rectum receiving between 30 Gy and 70 Gy expressed as a 
percentage of the total rectal volume.20 Sexual dysfunction 
was not analysed because few men had adequate, self-
reported, erectile function at baseline before hormone 
therapy was commenced.21 The symptoms of late toxicity 
after radiotherapy to the pelvis are non-speciﬁ c and might 
be present before treatment. We took the eﬀ ect of baseline 
function into account by calculating changes in scores 
from baseline (pre-hormone treatment) to those recorded 
at 2 years for each endpoint22 (appendix 1). If pre-hormone 
symptom scores were unavailable, pre-radiotherapy 
scores were used. If symptom scores improved (ie, there 
were fewer symptoms after than before radiotherapy), 
these were recorded as a zero score. If the ﬁ nal symptom 
score was zero, then change in toxicity was also scored as 
zero if the pre-hormone or pre-radiotherapy scores were 
not recorded. By deﬁ nition, there was no baseline 
measure ment of proctitis on the Radiation Therapy 
Oncology Group (RTOG) scale. Further information is 
available elsewhere.22
Standardised total average toxicity (STAT) scores were 
derived to assess late overall toxicity with the individual 
endpoints listed on appendix 1. The rationale and 
validation of the STAT score in patients with breast cancer 
has previously been reported.23 We also obtained STAT 
scores to measure overall acute toxicity in patients with 
breast cancer and, by combining acute bladder and bowel 
toxicity, in those with prostate cancer. STAT scores were 
derived with the following method. For an individual 
patient (k), a standardised Z score, Zk,i, was derived for 
each toxicity endpoint (i) for which that patient had a valid 
(non-missing) score, sk,i: Zk,i=(sk,i–meani)/SDi, where meani 
and standard deviation (SDi) were taken over all cases in 
the study population for which toxicity data were available. 
Conversion of individual toxicity scores to Z scores 
eliminated the problem of grades for one toxicity item not 
being directly comparable with grades for another item. 
Z scores deﬁ ned, for a particular endpoint, whether a 
patient’s score was high or low relative to the distribution 
of the scores of other patients in the population. The STAT 
score for patient k, STATk, was the average of all non-
missing Z scores for that patient: STATk=mean Zk,i.
To select SNPs, we undertook a comprehensive literature 
search of Medline and PubMed databases using the 
keywords “radiotherapy”, “radiation”, “toxicity”, “adverse 
eﬀ ects”, “genetic variation”, and “poly morphism”. This 
search identiﬁ ed 69 in-vitro or in-vivo studies published up 
to Dec 31, 2009. 66 SNPs reported to be associated with late 
radiotherapy toxicity were identiﬁ ed from these studies. 
Additionally, we examined the most frequently studied 
genes, ATM, TGFB1, XRCC1, XRCC3, and HIF1A, in more 
detail by choosing a set of tag SNPs to capture all common 
genetic variation in these ﬁ ve genes with r² greater 
than 0·8.24 Six new candidate SNPs were also selected: two 
in ATM (rs1800054, rs4986761) reported to be associated 
with breast cancer susceptibility; two in MRE11 (rs569143, 
rs2155209) reported to be associated with breast and 
bladder cancer susceptibility; and rs1800734 in MLH1 and 
rs2303428 in MSH2, reported to be associated with acute 
myeloid leukaemia after chemotherapy. Many of the SNPs 
included in the SNP signatures described in previous 
reports9–14 were genotyped in this study. Where possible, 
risk alleles in each of the signatures were summed and 
related to each toxicity endpoint with regression analysis.
DNA was extracted from blood by Gen-Probe Life 
Sciences (Manchester, UK) and all samples were 
normalised to 40 ng/μL before arraying in 384-well 
OR P0 (%) PC (%) P (%) ΔDesc (Gy)
MAF 50% 2·1 20% 34·4% 27·2% 2·1
MAF 35% 2·2 20% 35·0% 25·3% 1·5
MAF 20% 2·5 20% 38·3% 23·7% 1·1
MAF 10% 3·3 20% 45·0% 22·5% 0·7
MAF 5% 4·9 20% 55·2% 21·8% 0·5
OR=odds ratio. P0=incidence of toxicity in non-carriers (reference value). 
PC=incidence of toxicity in carriers. P=resulting incidence of toxicity in unselected 
cases. ΔDesc=permissible dose escalation in non-carriers to maintain isotoxicity 
with unselected population.
Table 1: Eﬀ ect sizes, quantiﬁ ed as the OR between carriers and 
non-carriers that can be resolved with 99% power and a nominal α of 
2·7×10–⁵
See Online for appendix 1
For more on Gen-Probe see 
http://www.gen-probe.com
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SNP MAF Base 
change
HWE 
p value
Originally reported signiﬁ cantly associated endpoints Assay
ABCA1 rs2230806 0·28 G→A 0·02 Acute radiation dermatitis13 Fluidigm
ALAD rs818707 0·12 G→A 0·84 Early adverse skin reactions32 Fluidigm
APEX1 rs1130409 0·48 T→G 0·56 Acute skin toxicity;29 delay in DNA strand-break rejoining;30 mitotic delay31 Fluidigm
ATM rs1800889 0·05 C→T 1·00 ATM tag SNP Fluidigm
ATM rs1800054 0·01 C→G 1·00 Frequently studied breast cancer susceptibility allele33,34 Fluidigm
ATM rs664677 0·42 T→C 0·35 Early or late adverse radiotherapy reaction according to RTOG/EORTC in breast 
cancer36
Fluidigm
ATM rs227060 0·31 T→C 0·85 Early or late adverse radiotherapy reaction according to RTOG/EORTC in breast 
cancer36
Fluidigm
ATM rs17503908 0·11 T→G 0·51 ATM tag SNP Fluidigm
ATM rs639923 0·05 G→A 0·13 ATM tag SNP Fluidigm
ATM rs11212592 0·18 G→A 0·83 ATM tag SNP Fluidigm
ATM rs11212570 0·09 G→A 1·00 ATM tag SNP Fluidigm
ATM rs4987889 0·02 T→C 0·34 ATM tag SNP Fluidigm
ATM rs4988023 0·14 C→A 0·79 ATM SNP correlated with (r²=1) rs1801516 associated with early or late adverse 
radiotherapy reaction according to RTOG/EORTC;36 late toxicity according to 
RTOG;38 severe radiation-induced sequelae (CTCAE version 3.0 grade ≥3);11 in-vitro 
clonogenic survival fraction;9 breast cancer susceptibility allele;34 development of 
telangiectasia37
Fluidigm
ATM rs1800056 0·02 T→C 0·09 Frequently studied breast cancer susceptibility allele;33,34 increased macronuclei 
formation in vitro40
Fluidigm
ATM rs1800058 0·02 C→T 0·0098 Frequently studied breast cancer susceptibility allele;33,34 lung ﬁ brosis, pleural 
thickening, and atrophy37
Fluidigm
ATM rs1800057 0·03 C→G 0·15 Frequently studied breast cancer susceptibility allele;33,34 increased macronuclei 
formation in vitro40
Fluidigm
ATM rs4986761 0·01 C→T 0·30 Frequently studied breast cancer susceptibility allele33 Fluidigm
BAX rs918546 0·48 G→T 0·01 Early adverse skin reactions32 Fluidigm
CD44 rs8193 0·34 C→T 0·82 Early adverse skin reactions32 Fluidigm
CDKN1A rs1801270 0·08 C→A 0·05 Included as a risk allele associated with in-vitro clonogenic survival fraction9 Fluidigm
DCLRE1C rs35441642 0·08 G→C 1·00 Radiosensitivity and a double-strand break repair defect in G2 phase35 Fluidigm
EPDR1 rs1376264 0·31 T→C 0·77 Dysuria at 3 months14 Fluidigm
ERCC2 rs1799793 0·34 G→A 0·67 Increased chromatid aberrations42,43 Taqman
ERCC2 rs1052555 0·32 T→C 0·74 Severe (grade ≥2) late bladder or rectal toxicity (RTOG)45 Fluidigm
ERCC2 rs1799787 0·30 C→T 0·76 Increased chromatid aberrations42 Taqman
ERCC4 rs1799801 0·29 T→C 0·65 Need for long-term percutaneous feeding gastrostomy tube47 Fluidigm
ERCC4 rs1800067 0·08 G→A 0·18 Need for long-term percutaneous feeding gastrostomy tube47 Fluidigm
GSTA1 rs3957356 0·00 T→C N/A Telangiectasia41 Failed
GSTP1 rs1695 0·35 G→A 0·65 Acute toxicity44 and increased pleural thickening46 Fluidigm
HIF1A rs12435848 0·19 G→A 0·18 HIF1A tag SNP Fluidigm
HIF1A rs2284999 0·10 T→C <0·0005 HIF1A tag SNP Fluidigm
HIF1A rs2301106 0·12 T→C 1·00 HIF1A tag SNP Fluidigm
HIF1A rs2301113 0·23 C→A 0·10 HIF1A tag SNP Fluidigm
HIF1A rs2301111 0·21 G→C 0·03 HIF1A tag SNP Fluidigm
HIF1A rs4899056 0·11 T→C <0·0005 HIF1A tag SNP Fluidigm
IL12RB2 rs3790568 0·05 G→A 0·12 Acute radiation dermatitis Fluidigm
LIG3 rs3744355 0·10 G→C 0·36 Early adverse skin reactions32 Fluidigm
LIG4 rs1805389 0 T→C N/A LIG4 syndrome patients51 Failed
LIG4 rs1805388 0·17 T→C 0·23 LIG4 syndrome patients51 Fluidigm
LIG4 rs1805386 0·17 T→C 0·10 Severe (grade ≥2) late bladder or rectal toxicity (RTOG)45 Fluidigm
LIG4 rs12856974 0·06 T→C 0·44 In strong linkage disequilibrium (r²=1·0) with LIG4 SNP rs1805389 Taqman
MAD2L2 rs2294638 0·48 G→C 0·61 Early adverse skin reactions32 Fluidigm
MAP3K7 rs3757244 0·00 A→T 1·00 Early adverse skin reactions32 Fluidigm
MAT1A rs2282367 0·32 G→A 0·53 Early adverse skin reactions32 Fluidigm
(Continues on next page)
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Originally reported signiﬁ cantly associated endpoints Assay
(Continued from previous page)
MLH1 rs1799977 0·32 A→G 0·36 Severe (grade ≥2) late bladder or rectal toxicity (RTOG)45 Fluidigm
MLH1 rs1800734 0·22 A→G 0·99 Acute myeloid leukaemia after methylating chemotherapy for Hodgkin disease53 Fluidigm
MPO rs2333227 0 T→C N/A Acute toxicity in women with increased BMI39 Failed
MRE11A rs569143 0·41 G→C 0·32 Breast cancer susceptibility52 Fluidigm
MRE11A rs2155209 0·33 T→C 0·93 Bladder cancer susceptibility50 Fluidigm
MSH2 rs2303428 0·10 T→C 0·90 Acute myeloid leukaemia after chemotherapy with alkylating agents54 Fluidigm
NEIL3 rs3805169 0·07 T→C 0·76 Early adverse skin reactions32 Fluidigm
NFE2L2 rs1806649 0·26 T→C 0·55 Early adverse skin reactions32 Fluidigm
NOS3 rs1799983 0·34 T→G 0·35 Telangiectasia41 and acute toxicity in women with increased BMI39 Fluidigm
PAH rs1126758 0·39 G→A 0·57 Dysuria at 3 months14 Fluidigm
PRKDC rs2213178 0·24 T→C 0·18 No statistical association with chromosomal radiosensitivity49 Fluidigm
PTTG1 rs3811999 0·39 T→C 0·93 Early adverse skin reactions32 Fluidigm
PTTG1 rs2961950 0·33 A→G 0·96 Early adverse skin reactions32 Fluidigm
PTTG1 rs2961952 0·27 G→A 0·74 Early adverse skin reactions32 Fluidigm
RAD17 rs3756402 0·06 G→A 0·0006 Early adverse skin reactions32 Fluidigm
RAD21 rs1050838 0·17 T→C 0·45 Clinically radiosensitive patients with various tumour types;67 
severe radiation-induced sequelae11
Fluidigm
RAD9A rs2286620 0·07 T→C 0·73 Early adverse skin reactions32 Fluidigm
RAD9A rs917570 0·44 G→C 0·50 Early adverse skin reactions32 Fluidigm
REV3L rs190246 0·11 C→A 0·83 Early adverse skin reactions32 Fluidigm
REV3L rs240962 0·11 T→C 0·92 Early adverse skin reactions32 Taqman
SART1 rs2276015 0·00 G→A 1·00 Dysuria at 3 months14 Fluidigm
SH3GL1 rs73234 0·45 G→C 0·13 Early adverse skin reactions32 Fluidigm
SOD2 rs4880 0·49 T→C 0·0070 Subcutaneous ﬁ brosis,10 late rectal bleeding,56 and severe radiation-induced 
sequelae11
Fluidigm
TGFB1 rs1466345 0·30 G→A 0·62 TGFB1 tag SNP Fluidigm
TGFB1 rs1800469 0·30 C→T 0·06 Subcutaneous ﬁ brosis10,57,58 and severe radiation-induced sequelae11 Fluidigm
TGFB1 rs1800470 0·38 T→C 0·08 Subcutaneous ﬁ brosis,10 clonogenic survival fraction9 Taqman
TGFB1 rs8110090 0·05 A→G 0·02 TGFB1 tag SNP Fluidigm
TGFB1 rs4803455 0·49 C→A 0·04 No association with toxicity in previous RAPPER study55 Fluidigm
TGFB1 rs1466338 0·34 G→C 0·45 TGFB1 tag SNP Fluidigm
TGFB3 rs2268622 0·17 T→C 0·20 Early adverse skin reactions32 Fluidigm
TGFBR3 rs1926261 0·24 G→A 0·52 Early adverse skin reactions32 Fluidigm
TP53 rs1042522 0·25 G→C 0·07 Telangiectasia,59 acute skin reaction,60 and clonogenic survival fraction9 Fluidigm
XPC rs2228000 0·26 T→C 0·58 DNA damage repair capacity by alkaline comet assay61 Fluidigm
XPC rs2228001 0·39 C→A 0·89 DNA damage repair capacity by alkaline comet assay61 Fluidigm
XRCC1 rs1799782 0·06 T→C 0·06 Toxicity score according to CTCAE version 3.0 after pelvic radiotherapy,12 
single-strand breaks and DNA repair rates;64 DNA damage measured by comet 
assay,30,63 adverse reaction to breast radiotherapy scored by EORTC66
Fluidigm
XRCC1 rs25487 0·36 G→A 0·72 Subcutaneous ﬁ brosis10 adverse reaction to breast radiotherapy scored by EORTC,66 
early adverse skin reactions,29,32 single-strand breaks and DNA repair rates,64 severe 
radiation-induced sequelae,11 DNA strand-break rejoining;30 in-vitro cell cycle G2 
delay,31 chromosome deletions, 42 DNA repair62
Fluidigm
XRCC1 rs25489 0·04 G→A 0·22 Erectile dysfunction;56 single-strand breaks and DNA repair rates62,64 Fluidigm
XRCC1 rs3213235 0·01 C→A 1·00 Haplotype analysis of patients with adverse radiotherapy response in the breast68 Fluidigm
XRCC1 rs2854496 0·19 G→A 0·45 XRCC1 tag SNP Fluidigm
XRCC1 rs3213282 0·44 G→C 0·52 XRCC1 tag SNP Fluidigm
XRCC1 rs1799778 0·36 C→A 0·72 XRCC1 tag SNP Fluidigm
XRCC1 rs3213266 0·08 T→C 0·02 XRCC1 tag SNP Fluidigm
XRCC1 rs3213334 0·23 T→C 0·35 XRCC1 tag SNP Fluidigm
XRCC1 rs2293036 0·07 A→G 0·0005 XRCC1 tag SNP Fluidigm
(Continues on next page)
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plates. DNA was genotyped for 95 SNPs with the 
Fluidigm high-throughput platform and Fluidigm 96.96 
Dynamic Arrays according to the manufacturer’s 
instructions and read with the Fluidigm EP1 (Fluidigm 
Corporation, San Francisco, CA, USA). Genotypes were 
automatically called with the BioMark Genotyping 
Analysis software (version 2.1.1), but all cluster plots 
were also checked manually and adjusted as necessary.
Six SNP assays failed quality control on the Fluidigm 
system and so these, as well as three SNPs chosen later, 
were genotyped with the Taqman 7900HT Sequence 
Detection System (Applied Biosystems, Warrington, UK). 
Genotypes were established with Allelic Discrim ination 
Sequence Detection software (version 2.1.1). Primer and 
probe details are available on request.
For both Fluidigm and Taqman genotyping, 5% of 
all samples were duplicated as a reproducibility control 
and negative controls were also included on all plates. 
The concordance rate between duplicate samples was 
100%. The average sample call rate was 99·6% (range 
98·0–99·9). Three SNPs (rs3957356, rs1805389, and 
rs2333227) failed quality control on both platforms and 
genotype distributions of a further three deviated from 
those expected under Hardy–Weinberg equilibrium 
with the Bonferroni correction for multiple testing 
(p<0·00051) and so were excluded from further analysis 
(rs2284999, rs2293036, rs4899056). Therefore, results 
from 92 SNPs were analysed.
Statistical analysis
Stata version 10.1 was used. Univariate analysis was 
initially done by linear regression of mean toxicity scores 
against genotype. Multivariable analysis of overall and 
individual endpoints of toxicity included all covariates, 
identiﬁ ed from univariate analyses, with p values of less 
than 0·05 (appendix 1).22,23,25 Many of these factors are 
known to be associated with toxicity, but are unlikely to be 
confounders of any genotype-toxicity association. In 
genetics, a confounding variable is genetically determined 
and could lead to spurious associations with a phenotype—
eg, genetic variation associated with large breast size 
leading to a large volume of normal tissue irradiated and 
so increased toxicity. Adjustment for covariates should 
result in any true association becoming more signiﬁ cant 
because of improvement in the signal-to-noise ratio. After 
multivariable analysis, residuals were calculated for each 
patient to quantify the toxicity not accounted for by 
available patient-related and treatment-related factors.23,26 
Patients with residuals of zero had toxicity entirely 
accounted for by the available patient-related and dose-
related factors. Patients with negative or positive residuals 
had less or greater toxicity, respectively, than was accounted 
for by known factors. The means of the residuals for 
overall toxicity (rSTAT) and individual endpoints were 
correlated with genotype with linear regression. For SNPs 
that were signiﬁ cantly associated with a particular toxicity 
endpoint, the endpoint was dichotomised to obtain a more 
clinically interpretable per-allele odds ratio (OR).
A Bonferroni correction was made to adjust for the 
eﬀ ects of multiple testing; the nominal signiﬁ cance 
threshold (p=0·05) was divided by the number of tests 
done (92 SNPs×20 endpoints) to give a signiﬁ cance 
threshold of p=2·7×10–⁵. Q-Q plots were created to assess 
the distribution of the 92 test statistics from that expected 
under the null hypothesis that no SNP was associated 
with late radiotherapy toxicity.
We undertook power calculations by specifying 
diﬀ erences to be detected between genotypes in the mean 
SNP MAF Base 
change
HWE 
p value
Originally reported signiﬁ cantly associated endpoints Assay
(Continued from previous page)
XRCC1 rs2023614 0·08 G→C 0·05 XRCC1 tag SNP Fluidigm
XRCC1 rs12611088 0·36 G→A 0·65 XRCC1 tag SNP Fluidigm
XRCC3 rs1799794 0·20 G→A 0·65 Severe (grade ≥2) late bladder or rectal toxicity (RTOG)45 Fluidigm
XRCC3 rs3212090 0·33 G→A 0·45 XRCC3 tag SNP Fluidigm
XRCC3 rs3212102 0·03 G→A 0·40 XRCC3 tag SNP Fluidigm
XRCC3 rs3212079 0·07 T→C 0·51 XRCC3 tag SNP Fluidigm
XRCC3 rs861534 0·37 G→A 0·37 In strong linkage disequilibrium with rs861539 (r²=0·96), which is associated with 
subcutaneous ﬁ brosis,10 toxicity according to CTCAE version 3.0 after pelvic 
radiotherapy,12 erectile dysfunction,56 acute toxicity,48 clonogenic survival fraction,9 
severe radiation-induced sequelae,11 chromosomal radiosensitivity,65 and 
chromosome deletions42
Fluidigm
XRCC5 rs3835 0·12 T→C 0·92 Chromosomal radiosensitivity49 Fluidigm
XRCC6 rs2267437 0·44 C→G 1·00 Dysuria at 3 months,13 development of severe dysphagia,48 and increased 
chromosomal radiosensitivity49
Taqman
XRCC6 rs132788 0·34 G→C 0·01 Decreased chromosomal radiosensitivity49 Fluidigm
SNP=single nucleotide polymorphism. MAF=minor allele frequency. HWE=Hardy–Weinberg equilibrium. RTOG=Radiation Therapy Oncology Group. EORTC=European 
Organisation for Research and Treatment of Cancer. CTCAE= Common Terminology Criteria for Adverse Events. BMI=body-mass index.
Table 2: 98 SNPs selected from the literature review
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of the toxicity endpoint and adjusting for groups of 
unequal size according to minor allele frequency (MAF; 
appendix 1). Power of 99% and a type I error rate (p value) 
of 2·7×10–⁵ were selected to reduce risk of false-negative 
and false-positive associations, respectively, and the 
detectable eﬀ ect sizes (ORs) were estimated with STPLAN 
software (version 4.3) downloaded from the Department 
of Biostatistics at the MD Anderson Cancer Center 
(Houston, TX, USA; table 1). If the incidence of toxicity 
in non-carriers (P0) is assumed to be 20%, the incidence 
of toxicity in carriers (PC) will depend on the eﬀ ect size of 
that allele. The incidence of toxicity in the unselected 
population (P) is estimated as MAF × Pc + (1 – MAF) × P0. 
To estimate the clinical relevance of the detectable eﬀ ects, 
a hypothetical scenario was considered in which the SNP 
was used to identify sensitive individuals and escalate the 
dose in the remaining, relatively more resistant, cases. 
The permis sible dose escalation (ΔDesc) that would result 
in the same incidence of toxicity in the non-carriers as 
would be seen in the unselected population was 
calculated. To this end, a logistic dose–response curve 
with a steepness of γ50=3 was assumed—ie, at the steepest 
part of the dose–response curve, corresponding to a 50% 
response level, there would be a 3% increase in response 
in percentage points for a 1% increase in dose, a typical 
value for late normal tissue eﬀ ects (appendix 1).27 The 
γ value at the 20% response level is 1·7.28 Using this value 
and the diﬀ erence between P and P0, we calculated ΔDesc 
using a linear approximation to the dose–response curve. 
This approximation was deemed adequate over the fairly 
narrow range of response probabilities considered.
Role of the funding source
The funding sources had no role in the design of the 
study, collection, analysis, interpretation of the data, 
writing of the report, or in the decision to submit for 
publication. GCB had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
66 SNPs previously reported to be associated with 
radiotherapy toxicity, either clinically or in in-vitro 
assays,9–14,29–68 were selected along with an additional 
28 SNPs in ATM, TGFB1, XRCC1, XRCC3, and HIF1A as 
tagging SNPs, designed to capture all common genetic 
variation within these genes, or because of evidence for 
direct functionality (table 2). Appendix 2 shows the 
unadjusted results from regression analysis of all 
92 analysed SNPs in 46 genes against all endpoints.
Some genetic variants, depending on their action, are 
likely to aﬀ ect toxicity in both breast and prostate cancer. 
For example, polymorphisms such as those in DNA repair 
genes would be likely to act soon after irradiation and 
therefore could aﬀ ect all late toxicity measures. In the 
combined cancer site analysis, we sought any such variants 
ﬁ rst, using the STAT score of overall late toxicity in the 
combined sets of patients with breast or prostate cancer. 
None were signiﬁ cant after adjustment for multiple testing. 
Figure 2 shows Q-Q plots of the observed versus expected 
p values of all 92 successfully genotyped SNPs with overall 
late toxicity. A quantile-quantile or Q-Q plot is obtained by 
ordering the p values obtained from association tests and 
plotting them against that which would be expected from 
chance alone. Deviation from the identity line (x=y) at the 
tail of the distribution suggests deviation from the null 
distribution (that expected under the null hypothesis that 
no SNP is associated with the trait) and the presence of 
true association. The distribution of observed p values does 
not deviate signiﬁ cantly from that expected by chance.
The strongest association in the analysis of acute toxicity 
in patients with breast or prostate cancer was for ATM 
SNP rs4988023 with the endpoint of acute bladder toxicity 
in patients with prostate cancer. However, the OR (per 
additional risk allele) was 1·53 (95% CI 1·08–2·18) for 
development of acute symptoms of grade 2 or higher 
(p=0·0006) and thus short of the value regarded as 
Figure 2: Q-Q plots showing p values (and corresponding χ² values) obtained from (A) univariate and (B) 
multivariable analyses of overall toxicity against genotype at the 92 SNPs
The solid lines represent the identity line (x=y). p values do not vary signiﬁ cantly from those that would be 
expected from chance alone. SNP=single nucleotide polymorphism. df=degree of freedom.
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signiﬁ cant after Bonferroni correction (p=2·7×10–⁵). 
Similarly, for late toxicity in patients with breast or prostate 
cancer, no associations were signiﬁ cant after conservative 
Bonferroni correction. The strongest association was 
between urinary frequency and rs1800734 in MLH1 
(p=0·0010). The OR (per additional risk allele) was 1·84 
(95% CI 1·26–2·70) for any increase in urinary frequency.
If we attempt to conﬁ rm only SNP associations 
with previously reported endpoints, a less stringent 
Bonferroni correction threshold could be deemed 
appropriate. In this analysis, 196 tests were done because 
many of the previous studies looked at non-speciﬁ c 
outcomes, such as early or late adverse radiotherapy 
reaction, and therefore the threshold for signiﬁ cance after 
a Bonferroni correction was 2·6×10–⁴. A few borderline 
signiﬁ cant associations were identiﬁ ed, but none reached 
this p-value threshold: the RAD21 SNP rs105083811,67 and 
SOD2 SNP rs488011 have previously been reported to be 
associated with severe radiosensitivity in various tumour 
types and were respectively associated with urinary 
incontinence (p=0·02) and proctitis (p=0·03). SART1 
rs2276015 was reported to be associated with dysuria at 
3 months,14 and here was associated with acute bladder 
toxicity (p=0·04). XRCC1 SNPs rs1799782 and rs25487 
were reported as being associated with adverse reactions 
to radiotherapy66 and here were associated with altered 
pigmentation (p=0·03) and telangiectasia (p=0·01).
Where possible, we tested the associations of previously 
reported SNP signatures, but not all the SNPs within 
such signatures were successfully genotyped in this 
study. We were unable to conﬁ rm association of increased 
toxicity with increasing number of risk alleles for any of 
the previously published signatures (table 3).
Discussion
None of the previous reports of signiﬁ cant associations 
between radiation toxicity and SNPs in candidate 
genes have been conﬁ rmed with appropriate levels of 
conﬁ dence within the design and sample size of our 
study (panel). The Q-Q plots show that there are no more 
signiﬁ cant associations among the 92 SNPs tested for 
overall late eﬀ ects than would have been expected by 
chance. This ﬁ nding is despite the fact that all the variants 
had already been reported as signiﬁ cantly associated with 
radiotherapy toxicity or otherwise judged to have a high 
previous probability of involvement. The associations of 
these highly selected variants are thus no better than 
those expected for any set of random SNPs picked from 
SNPs included in proﬁ le SNPs genotyped in 
present study
Endpoints associated with number of 
risk alleles in initial publication
Associations found in the present study
Andreassen and colleagues10 TGFB1 rs1800470
TGFB1 rs1800469
TGFB1 rs1800471
SOD2 rs4880
XRCC1 rs25487
XRCC3 rs861539
TGFB1 rs1800470
TGFB1 rs1800469
SOD2 rs4880
XRCC1 rs25487
XRCC3 rs861534*
Fibrosis in 41 postmastectomy patients No association with breast induration or breast shrinkage on 
univariate or multivariable analysis in 976 patients with breast 
cancer
Alsbeih and colleagues9 ATM rs1801516
TP53 rs1042522
CDKN1A rs1801270
XRCC1 rs25487
XRCC3 rs861539
TGFB1 rs1800470
ATM rs4988023†
TP53 rs1042522
CDKN1A rs1801270
XRCC1 rs25487
XRCC3 rs861534*
TGFB1 rs1800470
54 ﬁ broblast strains of varying 
radiosensitivity measured by clonogenic 
survival assay
No association with overall toxicity on univariate and 
multivariable analysis in patients with breast or prostate 
cancer combined
No association with breast induration or breast shrinkage on 
univariate or multivariable analysis in 976 patients with breast 
cancer
Azria and colleagues11 TGFB1 rs1800470
TGFB1 rs1800469
ATM rs1801516
SOD2 rs4880
XRCC1 rs25487
XRCC3 rs861539
RAD21 rs1050838
TGFB1 rs1800470
TGFB1 rs1800469
ATM rs4988023†
SOD2 rs4880
XRCC1 rs25487
XRCC3 rs861534*
RAD21 rs1050838
16 patients with severe radiation-induced 
sequelae and 18 control patients without 
adverse eﬀ ects; RTOG/EORTC grade in 
various cancers
No association with overall toxicity on univariate and 
multivariable analysis in patients with breast or prostate 
cancer combined
De Ruyck and colleagues12 XRCC1 rs25487
XRCC1 rs25489
XRCC1 rs3547‡
XRCC3 rs1799796‡
XRCC1 rs25487
XRCC1 rs25489
62 women with cervical or endometrial 
cancer; toxicity score according to CTCAE 
version 3.0
No signiﬁ cant increase in any toxicity endpoint in patients 
with breast or prostate cancer
Suga and colleagues14 SART1 rs2276015
ID3 rs2742946
EPDR1 rs376264
PAH rs1126758
 XRCC6 rs2267437
SART1 rs2276015§
EPDR1 rs376264
PAH rs1126758
XRCC6 rs2267437
197 patients with prostate cancer; dysuria 
at 3 months
No signiﬁ cant association with acute bladder toxicity at 
3 months
Isomura and colleagues13 ABCA1 rs2230806
IL12RB2 rs3790568
ABCA1 rs2230806
IL12RB2 rs3790568
156 women treated with adjuvant breast 
radiotherapy; acute toxicity
No signiﬁ cant increase in acute or late toxicity endpoints in 
patients with breast cancer
SNP=single nucleotide polymorphism. RTOG=Radiation Therapy Oncology Group. EORTC=European Organisation for Research and Treatment of Cancer. CTCAE=Common Terminology Criteria for Adverse 
Events. *In strong linkage disequilibrium with XRCC3 rs861539 with r²=0·96. †In strong linkage disequilibrium with ATM rs1801516 with r²=1. ‡SNPs not in HapMap and therefore the linkage disequilibrium with 
SNPs genotypes in the present study could not be calculated; XRCC1 and XRCC3 genes tagged completely in present study. §No rare homozygotes in present study.
Table 3: Results from testing of previously proposed SNP proﬁ les
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the genome. Our ﬁ ndings suggest that the published 
literature on this subject is dominated by false-positive 
associations due to small sample sizes, multiple testing, 
and the absence of rigorous independent validation 
attempts in the original studies.
For ﬁ ve genes thought to be particularly good candidates 
(ATM, TGFB1, XRCC1, XRCC3, and HIF1A), we not only 
re-examined the previously reported SNPs but also 
examined a more comprehensive set of tag SNPs designed 
to represent all the known common variants (MAF >0·05) 
within the genomic footprint of each gene. None of these 
SNPs revealed signiﬁ cant associations after correction for 
multiple testing. Our results therefore suggest that 
common variants within these genes are unlikely to aﬀ ect 
the development of radiotherapy toxicity.
The strongest although not signiﬁ cant association 
identiﬁ ed in this study was between ATM SNP rs4988023 
(MAF 0·14) and acute bladder toxicity in patients with 
prostate cancer. This SNP had been selected as a more 
reliably genotyped surrogate for another ATM SNP, 
rs1801516 (correlation r²=1). rs1801516 had previously 
been reported to be associated with several eﬀ ects 
including adverse radiotherapy reaction according to 
RTOG/European Organisation for Research and 
Treatment of Cancer (EORTC),36 late toxicity according to 
RTOG,38 severe radiation-induced sequelae (Common 
Terminology Criteria for Adverse Events version 3.0 
grade ≥3),11 in-vitro clonogenic survival fraction,69 and 
development of telangiectasia.34 It has been reported 
as a breast cancer susceptibility allele,37 although not 
conﬁ rmed in subsequent studies.70 In view of this 
additional background, the association we noted could be 
a true-positive association. ATM SNP rs1801516 results in 
a non-conservative aminoacid substitution of asparagine 
for aspartic acid at position 1853 of the protein. ATM 
codes for the main phosphatidylinositol 3-kinase related 
kinase responding to double-strand breaks. It is defective 
in the hereditary disorder ataxia telangiectasia, which is 
associated with hypersensitivity to radiation, immuno-
deﬁ ciency, and cancer predis position. The relation 
between heterozygous truncating mutations in ATM and 
radiosensitivity remains equivocal.
A possible limitation of our study was our necessary 
reliance on 2-year follow-up toxicity data in this still 
maturing study. Normal tissue reactions, such as induration 
and telangiectasia, develop gradually after a latency period 
over many years.71,72 Although there is evidence that late 
eﬀ ects at 2 years are predictive of those at 5 years,73 we 
might not have detected the full severity of developing late 
toxicity in some patients. A re-analysis of data is planned 
after longer follow-up, which will enable us to better 
address the eﬀ ect of late toxicity timepoint assessments. 
A further potential limitation of this study was the inability 
to assess erectile dysfunction. However, only two studies 
examined this endpoint. The only genome-wide association 
study undertaken so far into late toxicity from radiotherapy 
has reported an association that reached genome-wide 
signiﬁ cance between SNP rs2268363 in the follicle-
stimulating hormone receptor gene (FSHR; involved in 
testes development and spermatogenesis) and erectile dys-
function in a small cohort of African American men.4 
Collaborations developed through the Radiogenomics 
Consortium are enabling replication studies to be done.74,75
We have aimed to minimise both false-positive and 
false-negative ﬁ ndings in this validation study, since the 
need for multiple testing was generally ignored in the 
original hypothesis-generating studies. We used a 
conservative Bonferroni correction to reduce the chance 
of false-positive results, in view of the large number of 
tests we had done. In so doing, we might have missed 
some true associations with small eﬀ ect sizes for which 
the power of this study was low. However, use of such a 
stringent p value is justiﬁ ed; as table 1 shows, even with 
this conservative Bonferroni correction, we have enough 
power to detect clinically relevant ORs.
If a Bonferroni correction is made, the actual p value 
chosen to represent statistical signiﬁ cance can vary slightly 
according to estimates of the degree of correlation between 
the multiple hypotheses tested. For example, there might 
be correlation between some of the SNPs and between 
some of the endpoints. Yet, the need for a stringent p value 
is paramount, however many tests are done. The p value is 
the probability of the data given that the null hypothesis is 
true. The probability that we are actually interested in is 
the probability that the null hypothesis is true given the 
data,76 which depends on the p value, the power of the 
study to detect the eﬀ ect, and the previous probability the 
null hypothesis is true. None of these factors are changed 
by the number of tests done. The previous probability that 
any one SNP is associated with any endpoint is, at best, 
very small. For example, the previous probability might 
have increased from 1:100 000 to 1:10 000 given previous 
positive association. This estimate assumes there are 
10 million SNPs in the human genome; results from other 
Panel: Research in context
Systematic review
We undertook a comprehensive search of Medline and 
PubMed databases using the keywords “radiotherapy”, 
“radiation”, “toxicity”, “adverse eﬀ ects”, “genetic variation”, 
and “polymorphism”. This search identiﬁ ed 69 in-vitro or 
in-vivo studies published up to Dec 31, 2009. Studies to date 
have been underpowered, including fewer than 500 samples, 
have tested many single nucleotide polymorphisms without 
adjusting for multiple comparisons, and ﬁ ndings have proved 
diﬃ  cult to replicate.6–8
Interpretation
Our failure to replicate the associations of most variants 
reported from candidate gene studies suggests that common 
variation in the genes studied is increasingly unlikely to be 
clinically important in determining individual variation in 
response to radiotherapy.
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genome-wide association studies suggest no more than 
50 SNPs would be expected to account for 1% of the 
phenotypic variance with detectable eﬀ ect sizes and the 
previous probability is doubled for candidate gene 
selection. So, a very stringent p value is needed.
Correction for multiple testing might be unnecessarily 
stringent when we aimed to directly conﬁ rm previous 
reports. However, this assumption is only true if the 
validation study tests one previous association. We studied 
20 endpoints and included 28 new SNPs. Also, many of 
the previously reported endpoints were either non-
speciﬁ c—eg, early or late adverse radiotherapy reaction 
according to RTOG/EORTC36—or were in-vitro tests of 
radiosensitivity, which did not provide an eﬀ ect size to be 
tested here, and so we felt a form of correction was 
necessary. Further study of RAD21 SNP rs1050838, SOD2 
SNP rs4880, SART1 SNP rs2276015, and XRCC1 SNPs 
rs1799782 and rs25487 in even larger studies would be 
merited. However, our study had suﬃ  cient power to 
detect eﬀ ect sizes needed for an individual SNP to aﬀ ect 
clinical management. Our study was larger than the 
published studies reporting associations. It is, therefore, 
likely that the original reports were false positives. All 
studies have reduced power to detect associations for rare 
SNPs and thus an increased chance of ﬁ nding false-
negative associations. The detectable eﬀ ect sizes increase 
with decreasing MAF. However, with increasing rarity of 
these radiosensitive cases, the clinical beneﬁ t of their 
removal from the risk set tends to zero—ie, identiﬁ cation 
of such rare variants in a hypothetical subgroup is likely 
to be increasingly irrelevant for the treatment deliverable 
to most patients. Table 1 shows that, if carriers of a SNP 
with a MAF of 5% associated with an increase in toxicity 
from 20% to 55·2% (equal to an OR of 4·9) could be 
advised not to receive radiotherapy, this approach would 
only allow an increase in dose to the remaining patients 
of 0·5 Gy if we aim for isotoxicity in the non-carriers. For 
a MAF of 0·35, we had 99% power to detect an OR of 2·2. 
Therefore we can essentially exclude the hypothesis that 
published SNPs individually exert a clinically relevant 
eﬀ ect.
Our failure to conﬁ rm ﬁ ndings of candidate gene 
studies is by no means unprecedented in the ﬁ eld of 
genetic studies; in fact, this situation has been the norm 
for most candidate gene studies of cancer susceptibility. 
Before the development of genome-wide association 
studies, more than 500 SNPs were examined in more 
than 100 candidate genes for breast cancer susceptibility;77 
many of those genes were examined in our study. None 
of those associations were conﬁ rmed, although 
subsequently more than 30 genetic loci with unequivocal 
eﬀ ects on breast cancer risk have been identiﬁ ed and are 
continuing to be discovered through ever larger genome-
wide association studies.78–80 A few of these loci lie close to 
genes that had already been considered in candidate 
studies (eg, 8q24 upstream of MYC, 6q25 upstream of 
ESR1, and 11q upstream of CCND1) and are likely to 
be regulatory regions for these genes. Genome-wide 
association studies have served to emphasise the poverty 
of our understanding of the biological basis of most 
complex traits and diseases and one of the earliest 
advances to come from this new technology will be the 
recognition of new biochemical pathways, and hence 
drug targets, for these traits.
Despite the failure to validate previously identiﬁ ed 
genetic determinants of radiotoxicity in our study, there 
remains evidence that genetic variation might account for 
a proportion of the patient-to-patient variability in response 
to radiation therapy. Several recent studies have shown 
that chromosomal radiosensitivity of lymphocytes is largely 
determined by genetic factors.81–85 Rare radiosensitivity 
syndromes, such as ataxia telangi ectasia, certainly aﬀ ect 
radiosensitivity in individual mutation carriers, but the 
prevalence of such mutations is so low that they have little 
eﬀ ect on radiosensitivity in most patients with cancer.
The ultimate goal of radiogenomics is to develop a 
genetic risk proﬁ le including many SNPs for indi-
vidualisation of radiation dose prescriptions to optimise 
tumour control while minimising normal tissue damage. 
Importantly, there is interest in identiﬁ cation of both 
individuals with low and those with high risk of toxicity, 
and there is no conceptual diﬀ erence between the two. 
For example, if one allele of a polymorphic genetic locus 
is associated with a high risk of toxicity, by deﬁ nition the 
other allele can be regarded as a non-toxicity allele. 
Development of genetic risk proﬁ les could, therefore, 
stratify patients into subgroups with diﬀ erent prob-
abilities of developing toxicity; this approach would allow 
individualised dose prescription, to increase survival and 
decrease the morbidity associated with cancer. The ﬁ rst 
stage in development of such a proﬁ le is to identify 
genetic variants that are unequivocally associated with 
diﬀ erences in radiation toxicity, even if their individual 
eﬀ ect size is small. The establishment of the Radio-
genomics Consort ium in 2009 should provide a route to 
not only undertake large, suﬃ  ciently powered studies, 
but also to address meth odological challenges associated 
with radiogenomics.74,75
The RAPPER study is continuing and a stage 1 genome-
wide analysis of STAT score and individual late toxicity 
endpoints has been done. Validation and replication in 
an independent cohort is underway. Ultimately, the top 
5–10% of SNPs showing the most signiﬁ cant association 
with toxicity will be genotyped across the Radiogenomics 
Consortium and included in a meta-analysis with other 
similar genome-wide association studies.
In conclusion, our failure to replicate the associations of 
most variants reported from candidate gene studies 
suggests that common variation in the genes studied is 
increasingly unlikely to be important in determining 
individual variation in response to radiotherapy. We cannot 
yet exclude a role for variants in these genes with very low 
MAF or small eﬀ ects, both of which would limit the clinical 
importance of these associations.
Articles
www.thelancet.com/oncology   Vol 13   January 2012 75
Contributors
GCB, CMLW, NGB, PDPP, and AMD were involved in the conception 
and design of the study. RME and GCB were involved in data 
acquisition. CB, CL, DC, GCB, and RP were involved in laboratory work. 
CEC is the principal investigator of the Cambridge Breast IMRT Trial. 
JSW, CEC, and GCB were involved in patient data acquisition for the 
Cambridge Breast IMRT trial. SLG, MRS, and DPD were involved in 
data collection and analysis of the RT01 trial. EH and DPD were involved 
in data collection and analysis of the CHHiP trial. DPD designed, 
initiated and was chief investigator for the RT01 and CHHiP trials. 
VM was involved in data collection in the Manchester prospective 
toxicity study. GCB, JT, PDPP, and SMB were involved in data analysis 
and interpretation. All authors were involved in writing or critical review 
of the draft report and all approved the ﬁ nal version.
Conﬂ icts of interest
We declare that we have no conﬂ icts of interest.
Acknowledgments
We thank John Barnett for help in preparation and proofreading of the 
article and Kristy Driver for help with database management. GCB is 
funded by a fellowship from Cancer Research UK and The Royal College 
of Radiologists (C26900/A8740) and also received funding from 
Addenbrooke’s Charitable Trust. JSW, breast research radiographer, is 
funded by the Breast Cancer Campaign. CEC and NGB are supported by 
the Cambridge National Institute of Health Research (NIHR) Biomedical 
Research Centre. AMD is funded by Cancer Research UK (C8197/A10865) 
and the Joseph Mitchell Trust. CMLW is supported by Cancer Research 
UK and Experimental Cancer Medicine Centre (ECMC) funding. SLG and 
DPD are supported by the Royal Marsden NHS Foundation Trust and 
Institute of Cancer Research NIHR Biomedical Research Centre for 
Cancer. RT01 was supported by the UK Medical Research Council. 
CHHiP was supported by the UK Department of Health and Cancer 
Research UK; trial recruitment was facilitated within centres by the 
NIHR-funded National Cancer Research Network. The collaborative 
group (RAPPER) is funded by Cancer Research UK. Laboratory 
infrastructure was funded by Cancer Research UK (C8197/A10123).
References
1 Bentzen SM, Constine LS, Deasy JO, et al. Quantitative analyses of 
normal tissue eﬀ ects in the clinic (QUANTEC): an introduction to 
the scientiﬁ c issues. Int J Radiat Oncol Biol Phys 2010; 76: S3–9.
2 Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: 
recommendations for reporting and gathering data on dose-volume 
dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 
2010; 76: S155–60.
3 Burnet NG, Elliott RM, Dunning A, West CM. Radiosensitivity, 
radiogenomics and RAPPER. Clin Oncol (R Coll Radiol) 2006; 
18: 525–28.
4 Kerns SL, Ostrer H, Stock R, et al. Genome-wide association study 
to identify single nucleotide polymorphisms (SNPs) associated with 
the development of erectile dysfunction in African-American men 
after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 
2010; 78: 1292–300.
5 Bentzen SM. Preventing or reducing late side eﬀ ects of radiation 
therapy: radiobiology meets molecular pathology. Nat Rev Cancer 
2006; 6: 702–13.
6 Alsner J, Andreassen CN, Overgaard J. Genetic markers 
for prediction of normal tissue toxicity after radiotherapy. 
Semin Radiat Oncol 2008; 18: 126–35.
7 Barnett GC, West CM, Dunning AM, et al. Normal tissue reactions 
to radiotherapy: towards tailoring treatment dose by genotype. 
Nat Rev Cancer 2009; 9: 134–42.
8 Popanda O, Marquardt JU, Chang-Claude J, Schmezer P. 
Genetic variation in normal tissue toxicity induced by 
ionizing radiation. Mutat Res 2009; 667: 58–69.
9 Alsbeih G, El-Sebaie M, Al-Harbi N, Al-Buhairi M, Al-Hadyan K, 
Al-Rajhi N. Radiosensitivity of human ﬁ broblasts is associated with 
amino acid substitution variants in susceptible genes and correlates 
with the number of risk alleles. Int J Radiat Oncol Biol Phys 2007; 
68: 229–35.
10 Andreassen CN, Alsner J, Overgaard M, Overgaard J. Prediction of 
normal tissue radiosensitivity from polymorphisms in candidate 
genes. Radiother Oncol 2003; 69: 127–35.
11 Azria D, Ozsahin M, Kramar A, et al. Single nucleotide 
polymorphisms, apoptosis, and the development of severe 
late adverse eﬀ ects after radiotherapy. Clin Cancer Res 2008; 
14: 6284–88.
12 De Ruyck K, Van Eijkeren M, Claes K, et al. Radiation-induced 
damage to normal tissues after radiotherapy in patients treated 
for gynecologic tumors: association with single nucleotide 
polymorphisms in XRCC1, XRCC3, and OGG1 genes and 
in vitro chromosomal radiosensitivity in lymphocytes. 
Int J Radiat Oncol Biol Phys 2005; 62: 1140–49.
13 Isomura M, Oya N, Tachiiri S, et al. IL12RB2 and ABCA1 genes 
are associated with susceptibility to radiation dermatitis. 
Clin Cancer Res 2008; 14: 6683–89.
14 Suga T, Iwakawa M, Tsuji H, et al. Inﬂ uence of multiple genetic 
polymorphisms on genitourinary morbidity after carbon ion 
radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 
2008; 72: 808–13.
15 Barnett GC, Wilkinson JS, Moody AM, et al. Randomized 
controlled trial of forward-planned intensity-modulated 
radiotherapy for early breast cancer: interim results at 2 years. 
Int J Radiat Oncol Biol Phys 2011; published online Feb 22. 
DOI:10.1016/j.ijrobp.2010.10.068.
16 Dearnaley DP, Sydes MR, Graham JD, et al, on behalf of the 
RT01 collaborators. Escalated-dose versus standard-dose conformal 
radiotherapy in prostate cancer: ﬁ rst results from the MRC RT01 
randomised controlled trial. Lancet Oncol 2007; 8: 475–87.
17 Sydes MR, Stephens RJ, Moore AR, et al, RT01 collaborators. 
Implementing the UK Medical Research Council (MRC) RT01 trial 
(ISRCTN 47772397): methods and practicalities of a randomised 
controlled trial of conformal radiotherapy in men with localised 
prostate cancer. Radiother Oncol 2004; 72: 199–211.
18 Syndikus I, Morgan RC, Sydes MR, Graham JD, Dearnaley DP. 
Late gastrointestinal toxicity after dose-escalated conformal 
radiotherapy for early prostate cancer: results from the UK 
Medical Research Council RT01 trial (ISRCTN47772397). 
Int J Radiat Oncol Biol Phys 2010; 77: 773–83.
19 Khoo VS, Dearnaley DP. Question of dose, fractionation 
and technique: ingredients for testing hypofractionation in 
prostate cancer—the CHHiP trial. Clin Oncol (R Coll Radiol) 
2008; 20: 12–14.
20 Gulliford SL, Foo K, Morgan RC, et al. Dose-volume constraints to 
reduce rectal side eﬀ ects from prostate radiotherapy: evidence from 
MRC RT01 trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys 2010; 
76: 747–54.
21 Mangar SA, Sydes MR, Tucker HL, et al. Evaluating the relationship 
between erectile dysfunction and dose received by the penile bulb: 
using data from a randomised controlled trial of conformal 
radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397). 
Radiother Oncol 2006; 80: 355–62.
22 Barnett GC,  De Meerleer G, Gulliford SL, Sydes MR, Elliott RM, 
Dearnaley DP. The impact of clinical factors on the development 
of late radiation toxicity: results from the Medical Research Council 
RT01 Trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) 2011; 
23: 613–24.
23 Barnett GC, West CM, Coles CE, et al. Standardized total average 
toxicity score: a scale- and grade-independent measure of late 
radiotherapy toxicity to facilitate pooling of data from diﬀ erent 
studies. Int J Radiat Oncol Biol Phys 2011; published online May 21. 
DOI:10.1016/j.ijrobp.2011.03.015.
24 Balding DJ. A tutorial on statistical methods for population 
association studies. Nat Rev Genet 2006; 7: 781–91.
25 Barnett GC, Wilkinson JS, Moody AM, et al. The Cambridge 
Breast Intensity-modulated Radiotherapy Trial: patient- and 
treatment-related factors that inﬂ uence late toxicity. 
Clin Oncol (R Coll Radiol) 2011; published online June 4. 
DOI:10.1016/j.clon.2011.04.011.
26 Bentzen SM, Overgaard J. Patient-to-patient variability in 
the expression of radiation-induced normal tissue injury. 
Semin Radiat Oncol 1994; 4: 68–80.
27 Bentzen SM. Radiobiological considerations in the design of clinical 
trials. Radiother Oncol 1994; 32: 1–11.
28 Bentzen SM. Dose-response relationships in radiotherapy. 
In: Joiner M, van der Kogel A, eds. Basic clinical radiobiology. 
London: Hodder Arnold, 2009: 56–67.
Articles
76 www.thelancet.com/oncology   Vol 13   January 2012
29 Chang-Claude J, Popanda O, Tan XL, et al. Association between 
polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD 
and acute side eﬀ ects of radiotherapy in breast cancer patients. 
Clin Cancer Res 2005; 11: 4802–09.
30 Farkasova T, Gurska S, Witkovsky V, Gabelova A. Signiﬁ cance 
of amino acid substitution variants of DNA repair genes in 
radiosusceptibility of cervical cancer patients; a pilot study. 
Neoplasma 2008; 55: 330–37.
31 Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, Case LD. 
Amino acid substitution variants of APE1 and XRCC1 genes 
associated with ionizing radiation sensitivity. Carcinogenesis 2001; 
22: 917–22.
32 Suga T, Ishikawa A, Kohda M, et al. Haplotype-based analysis 
of genes associated with risk of adverse skin reactions after 
radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 
2007; 69: 685–93.
33 Fletcher O, Johnson N, dos Santos Silva I, et al; Breast Cancer 
Association Consortium. Missense variants in ATM in 26,101 breast 
cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev 
2010; 19: 2143–51.
34 Renwick A, Thompson D, Seal S, et al. ATM mutations that 
cause ataxia-telangiectasia are breast cancer susceptibility alleles. 
Nat Genet 2006; 38: 873–75.
35 Woodbine L, Grigoriadou S, Goodarzi AA, et al. An Artemis 
polymorphic variant reduces Artemis activity and confers cellular 
radiosensitivity. DNA Repair (Amst) 2010; 9: 1003–10.
36 Angèle S, Romestaing P, Moullan N, et al. ATM haplotypes and 
cellular response to DNA damage: association with breast cancer 
risk and clinical radiosensitivity. Cancer Res 2003; 63: 8717–25.
37 Edvardsen H, Tefre T, Jansen L, et al. Linkage disequilibrium 
pattern of the ATM gene in breast cancer patients and controls; 
association of SNPs and haplotypes to radio-sensitivity and 
post-lumpectomy local recurrence. Radiation Oncol 2007; 2: 25.
38 Ho AY, Fan G, Atencio DP, et al. Possession of ATM 
sequence variants as predictor for late normal tissue 
responses in breast cancer patients treated with radiotherapy. 
Int J Radiat Oncol Biol Phys 2007; 69: 677–84.
39 Ahn J, Ambrosone CB, Kanetsky PA, et al. Polymorphisms in genes 
related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and 
acute toxicities from radiation therapy following lumpectomy for 
breast cancer. Clin Cancer Res 2006; 12: 7063–70.
40 Gutiérrez-Enríquez S, Fernet M, Dörk T, et al. Functional 
consequences of ATM sequence variants for chromosomal 
radiosensitivity. Genes Chromosomes Cancer 2004; 40: 109–19.
41 Kuptsova N, Chang-Claude J, Kropp S, et al. Genetic predictors 
of long-term toxicities after radiation therapy for breast cancer. 
Int J Cancer 2008; 122: 1333–39.
42 Au WW, Salama SA, Sierra-Torres CH. Functional characterization 
of polymorphisms in DNA repair genes using cytogenetic challenge 
assays. Environ Health Perspect 2003; 111: 1843–50.
43 Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: 
eﬀ ects on DNA repair proﬁ ciency. Carcinogenesis 2000; 21: 551–55.
44 Ambrosone CB, Tian C, Ahn J, et al. Genetic predictors of 
acute toxicities related to radiation therapy following lumpectomy 
for breast cancer: a case-series study. Breast Cancer Res 2006; 
8: R40.
45 Damaraju S, Murray D, Dufour J, et al. Association of DNA repair 
and steroid metabolism gene polymorphisms with clinical late 
toxicity in patients treated with conformal radiotherapy for prostate 
cancer. Clin Cancer Res 2006; 12: 2545–54.
46 Edvardsen H, Kristensen VN, Grenaker Alnaes GI, et al. 
Germline glutathione S-transferase variants in breast cancer: 
relation to diagnosis and cutaneous long-term adverse eﬀ ects 
after two fractionation patterns of radiotherapy. 
Int J Radiat Oncol Biol Phys 2007; 67: 1163–71.
47 Kornguth DG, Garden AS, Zheng Y, Dahlstrom KR, Wei Q, 
Sturgis EM. Gastrostomy in oropharyngeal cancer patients with 
ERCC4 (XPF) germline variants. Int J Radiat Oncol Biol Phys 2005; 
62: 665–71.
48 Werbrouck J, De Ruyck K, Duprez F, et al. Acute normal tissue 
reactions in head-and-neck cancer patients treated with IMRT: 
inﬂ uence of dose and association with genetic polymorphisms 
in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 2009; 
73: 1187–95.
49 Willems P, Claes K, Baeyens A, et al. Polymorphisms in 
nonhomologous end-joining genes associated with breast cancer 
risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 
2008; 47: 137–48.
50 Choudhury A, Elliott F, Iles MM, et al. Analysis of variants in DNA 
damage signalling genes in bladder cancer. BMC Med Genet 2008; 
9: 69.
51 Girard PM, Kysela B, Harer CJ, Doherty AJ, Jeggo PA. Analysis 
of DNA ligase IV mutations found in LIG4 syndrome patients: 
the impact of two linked polymorphisms. Hum Mol Genet 2004; 
13: 2369–76.
52 Hsu HM, Wang HC, Chen ST, Hsu GC, Shen CY, Yu JC. 
Breast cancer risk is associated with the genes encoding 
the DNA double-strand break repair Mre11/Rad50/Nbs1 
complex. Cancer Epidemiol Biomarkers Prev 2007; 16: 2024–32.
53 Worrillow LJ, Smith AG, Scott K, et al. Polymorphic MLH1 
and risk of cancer after methylating chemotherapy for Hodgkin 
lymphoma. J Med Genet 2008; 45: 142–46.
54 Worrillow LJ, Travis LB, Smith AG, et al. An intron splice acceptor 
polymorphism in hMSH2 and risk of leukemia after treatment with 
chemotherapeutic alkylating agents. Clin Cancer Res 2003; 9: 3012–20.
55 Barnett GC, Coles CE, Burnet NG, et al. No association between 
SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity 
to the breast: results from the RAPPER study. Radiother Oncol 2010; 
97: 9–14.
56 Burri RJ, Stock RG, Cesaretti JA, et al. Association of single 
nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with 
susceptibility for the development of adverse eﬀ ects resulting from 
radiotherapy for prostate cancer. Radiat Res 2008; 170: 49–59.
57 Giotopoulos G, Symonds RP, Foweraker K, et al. The late 
radiotherapy normal tissue injury phenotypes of telangiectasia, 
ﬁ brosis and atrophy in breast cancer patients have distinct 
genotype-dependent causes. Br J Cancer 2007; 96: 1001–07.
58 Quarmby S, Fakhoury H, Levine E, et al. Association of 
transforming growth factor beta-1 single nucleotide polymorphisms 
with radiation-induced damage to normal tissues in breast cancer 
patients. Int J Radiat Biol 2003; 79: 137–43.
59 Chang-Claude J, Ambrosone CB, Lilla C, et al. Genetic 
polymorphisms in DNA repair and damage response genes and late 
normal tissue complications of radiotherapy for breast cancer. 
Br J Cancer 2009; 100: 1680–86.
60 Tan XL, Popanda O, Ambrosone CB, et al. Association between 
TP53 and p21 genetic polymorphisms and acute side eﬀ ects of 
radiotherapy in breast cancer patients. Breast Cancer Res Treat 
2006; 97: 255–62.
61 Zhu Y, Yang H, Chen Q, et al. Modulation of DNA damage/DNA 
repair capacity by XPC polymorphisms. DNA Repair (Amst) 2008; 
7: 141–48.
62 Aka P, Mateuca R, Buchet JP, Thierens H, Kirsch-Volders M. 
Are genetic polymorphisms in OGG1, XRCC1 and XRCC3 
genes predictive for the DNA strand break repair phenotype and 
genotoxicity in workers exposed to low dose ionising radiations? 
Mutat Res 2004; 556: 169–81.
63 Godderis L, De Boeck M, Haufroid V, et al. Inﬂ uence of genetic 
polymorphisms on biomarkers of exposure and genotoxic eﬀ ects in 
styrene-exposed workers. Environ Mol Mutagen 2004; 44: 293–303.
64 Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms 
in DNA repair genes and possible links with DNA repair rates, 
chromosomal aberrations and single-strand breaks in DNA. 
Carcinogenesis 2004; 25: 757–63.
65 Wilding CS, Curwen GB, Tawn EJ, et al. Inﬂ uence of 
polymorphisms at loci encoding DNA repair proteins 
on cancer susceptibility and G2 chromosomal radiosensitivity. 
Environ Mol Mutagen 2007; 48: 48–57.
66 Moullan N, Cox DG, Angèle S, Romestaing P, Gérard JP, Hall J. 
Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, 
and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 
2003; 12: 1168–74.
67 Severin DM, Leong T, Cassidy B, et al. Novel DNA sequence 
variants in the hHR21 DNA repair gene in radiosensitive cancer 
patients. Int J Radiat Oncol Biol Phys 2001; 50: 1323–31.
68 Brem R, Cox DG, Chapot B, et al. The XRCC1 –77T→C variant: 
haplotypes, breast cancer risk, response to radiotherapy and the 
cellular response to DNA damage. Carcinogenesis 2006; 27: 2469–74.
Articles
www.thelancet.com/oncology   Vol 13   January 2012 77
69 Alsbeih G, Torres M, Al-Harbi N, Al-Buhairi M. Evidence that 
individual variations in TP53 and CDKN1A protein responsiveness 
are related to inherent radiation sensitivity. Radiat Res 2007; 
167: 58–65.
70 Gao LB, Pan XM, Sun H, et al. The association between 
ATM D1853N polymorphism and breast cancer susceptibility: 
a meta-analysis. J Exp Clin Cancer Res 2010; 29: 117.
71 Bentzen SM, Thames HD, Overgaard M. Latent-time estimation for 
late cutaneous and subcutaneous radiation reactions in a 
single-follow-up clinical study. Radiother Oncol 1989; 15: 267–74.
72 Dikomey E, Borgmann K, Peacock J, Jung H. Why recent studies 
relating normal tissue response to individual radiosensitivity might 
have failed and how new studies should be performed. 
Int J Radiat Oncol Biol Phys 2003; 56: 1194–200.
73 Turesson I. Individual variation and dose dependency in the 
progression rate of skin telangiectasia. Int J Radiat Oncol Biol Phys 
1990; 19: 1569–74.
74 Pharoah P. How not to interpret a p value? J Natl Cancer Inst 2007; 
99: 332–33.
75 Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. 
Association between common variation in 120 candidate 
genes and breast cancer risk. PLoS Genet 2007; 3: e42.
76 Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered 
breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 
2009; 41: 585–90.
77 Easton DF, Pooley KA, Dunning AM, et al. Genome-wide 
association study identiﬁ es novel breast cancer susceptibility 
loci. Nature 2007; 447: 1087–93.
78 Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association 
study identiﬁ es ﬁ ve new breast cancer susceptibility loci. Nat Genet 
2010; 42: 504–07.
79 Wu X, Spitz MR, Amos CI, et al. Mutagen sensitivity has 
high heritability: evidence from a twin study. Cancer Res 
2006; 66: 5993–96.
80 Borgmann K, Haeberle D, Doerk T, Busjahn A, Stephan G, 
Dikomey E. Genetic determination of chromosomal radiosensitivities 
in G0- and G2-phase human lymphocytes. Radiother Oncol 2007; 
83: 196–202.
81 Finnon P, Robertson N, Dziwura S, et al. Evidence for signiﬁ cant 
heritability of apoptotic and cell cycle responses to ionising radiation. 
Hum Genet 2008; 123: 485–93.
82 Curwen GB, Winther JF, Tawn EJ, et al. G(2) chromosomal 
radiosensitivity in Danish survivors of childhood and adolescent 
cancer and their oﬀ spring. Br J Cancer 2005; 93: 1038–45.
83 Schmitz A, Bayer J, Dechamps N, Goldin L, Thomas G. Heritability of 
susceptibility to ionizing radiation-induced apoptosis of human 
lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 2007; 
68: 1169–77.
84 West C, Rosenstein BS, Alsner J, et al. Establishment of 
a radiogenomics consortium. Int J Radiat Oncol Biol Phys 
2010; 76: 1295–96.
85 West C, Rosenstein BS. Establishment of a radiogenomics consortium. 
Radiother Oncol 2010; 94: 117–18.
